Suppression of tumor cell proliferation by quinine via the inhibition of the tumor necrosis factor receptor‑associated factor 6‑AKT interaction

Liu,Wenjuan; Qi,Yonghao; Liu,Lingyu; Tang,Yu; Wei,Jing; Zhou,Lijun

doi:10.3892/mmr.2016.5492

Suppression of tumor cell proliferation by quinine via the inhibition of the tumor necrosis factor receptor‑associated factor 6‑AKT interaction

Authors:
- Wenjuan Liu
- Yonghao Qi
- Lingyu Liu
- Yu Tang
- Jing Wei
- Lijun Zhou
View Affiliations

Affiliations: Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, P.R. China
Published online on: July 11, 2016 https://doi.org/10.3892/mmr.2016.5492
Pages: 2171-2179

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein kinase B (AKT), is a pivotal component of pathways associated with cell survival, metabolism, invasion and metastasis. AKT mediates anti‑apoptotic and proliferative signaling in response to essential cytokines. Tumor necrosis factor receptor‑associated factor (TRAF)6, an E3 ubiquitin ligase, has been shown to ubiquitylate, as well as activate AKT. The present study used computational methods to determine the relevant amino acid residues at the binding site of TRAF6 and selected small molecules, which may bind to TRAF6. An ex vivo assay was performed to determine their antitumor activities and the possible mechanism of action. Quinine, a natural alkaloid that is well‑known for its therapeutic treatment of malaria, exhibited a distinct antiproliferative and pro‑apoptotic effect in HeLa and A549 tumor cell lines via the inhibition of the antiapoptotic protein, B‑cell lymphoma (BCL)‑2, and activation of the pro‑apoptotic factor, BCL‑2‑associated X protein. Quinine inhibited the lipopolysaccharide (LPS)‑induced activation of AKT by inhibiting its phosphorylation at Thr‑308 and Ser‑473, and reversing LPS‑induced proliferation. These results suggested that the inhibition of AKT activation via targeting of TRAF6 with quinine may be a viable anticancer therapeutic approach and a successful example of the alternative use of the original therapeutic properties of this well‑known natural product.

View Figures

View References

1	Bae S, Kim SY, Jung JH, Yoon Y, Cha HJ, Lee H, Kim K, Kim J, An IS, Kim J, et al: Akt is negatively regulated by the MULAN E3 ligase. Cell Res. 22:873–885. 2012. View Article : Google Scholar : PubMed/NCBI
2	Cai J, Yang J and Jones DP: Mitochondrial control of apoptosis: The role of cytochrome c. Biochim Biophys Acta. 1366:139–149. 1998. View Article : Google Scholar : PubMed/NCBI
3	Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU and Brady JN: Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene. 24:6719–6728. 2005. View Article : Google Scholar : PubMed/NCBI
4	Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG and Lin HK: The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 325:1134–1138. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zhong L, Cao F and You Q: Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell. Tumor Biol. 34:231–239. 2013. View Article : Google Scholar
6	Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C and Chen ZJ: Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 103:351–361. 2000. View Article : Google Scholar : PubMed/NCBI
7	Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, et al: EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest. 124:3741–3756. 2014. View Article : Google Scholar : PubMed/NCBI
8	Wang DH, Qu WL, Shi LQ and Wei J: Molecular docking and pharmacophore model studies of Rho kinase inhibitors. Mol Simulat. 37:488–494. 2011. View Article : Google Scholar
9	Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC and Ferrin TE: UCSF chimera-A visualization system for exploratory research and analysis. J Comput Chem. 25:1605–1612. 2004. View Article : Google Scholar : PubMed/NCBI
10	Hartupee J, Liu C, Novotny M, Sun D, Li X and Hamilton TA: IL-17 signaling for mRNA stabilization does not require TNF receptor-associated factor 6. J Immunol. 182:1660–1666. 2009. View Article : Google Scholar : PubMed/NCBI
11	Elumalai P, Arunkumar R, Benson CS, Sharmila G and Arunakaran J: Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231). Cell Biochem Funct. 32:476–484. 2014.PubMed/NCBI
12	Schnetzke U, Fischer M, Kuhn AK, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP and Scholl S: The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. J Cancer Res Clin Oncol. 139:605–615. 2013. View Article : Google Scholar
13	Gills JJ and Dennis PA: The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin Investig Drugs. 13:787–797. 2004. View Article : Google Scholar
14	Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
15	Nishimura M and Naito S: Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull. 28:886–892. 2005. View Article : Google Scholar : PubMed/NCBI
16	Mao R, Fan Y, Mou Y, Zhang H, Fu S and Yang J: TAK1 lysine 158 is required for TGF-β-induced TRAF6-mediated Smad-independent IKK/NF-κB and JNK/AP-1 activation. Cell Signal. 23:222–227. 2011. View Article : Google Scholar
17	Chantzoura E, Prinarakis E, Panagopoulos D, Mosialos G and Spyrou G: Glutaredoxin-1 regulates TRAF6 activation and the IL-1 receptor/TLR4 signalling. Biochem Biophys Res Commun. 403:335–339. 2010. View Article : Google Scholar : PubMed/NCBI
18	Golbano JM, Lóppez-Aparicio P, Recio MN and Pérez-Albarsanz MA: Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol. 32:919–924. 2008.PubMed/NCBI
19	Alonso-Castro AJ, Ortiz-Sánchez E, García-Regalado A, Ruiz G, Núñez-Martínez JM, González-Sánchez I, Quintanar-Jurado V, Morales-Sánchez E, Dominguez F, López-Toledo G, et al: Kaempferitrin induces apoptosis via intrinsic pathway in HeLa cells and exerts antitumor effects. J Ethnopharmacol. 145:476–489. 2013. View Article : Google Scholar
20	Xu C, Wu A, Zhu H, Fang H, Xu L, Ye J and Shen J: Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance. Biomed Pharmacother. 67:133–139. 2013. View Article : Google Scholar
21	Costa LS, Telles CB, Oliveira RM, Nobre LT, Dantas-Santos N, Camara RB, Costa MS, Almeida-Lima J, Melo-Silveira RF, Albuquerque IR, et al: Heterofucan from Sargassum filipendula induces apoptosis in HeLa Cells. Mar Drugs. 9:603–614. 2011. View Article : Google Scholar : PubMed/NCBI
22	Hu W and Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 4:721–729. 2003. View Article : Google Scholar : PubMed/NCBI
23	Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
24	Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
25	Zhang L, Xing D and Chen MJ: Bim(L) displacing Bcl-x(L) promotes bax translocation during TNF alpha-induced apoptosis. Apoptosis. 13:950–958. 2008. View Article : Google Scholar : PubMed/NCBI
26	Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL and Henson PM: Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem. 279:21085–21095. 2004. View Article : Google Scholar : PubMed/NCBI
27	Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA, Bouchard RJ, Florez-McClure ML and Heidenreich KA: Glycogen synthase kinase-3 beta phosphorylates bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci. 24:9993–10002. 2004. View Article : Google Scholar : PubMed/NCBI
28	Zha J, Harada H, Yang E, Jockel J and Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell. 87:619–628. 1996. View Article : Google Scholar : PubMed/NCBI
29	Marte BM and Downward J: PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 22:355–358. 1997. View Article : Google Scholar : PubMed/NCBI
30	Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927. 1999. View Article : Google Scholar : PubMed/NCBI
31	Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
32	Scheid MP and Woodgett JR: Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 546:108–112. 2003. View Article : Google Scholar : PubMed/NCBI